{"title": "Clinical implications of anti-idiotype antibodies in COVID-19", "author": "Ajay Kumar Shukla; Saurav Misra", "url": "https://www.degruyter.com/document/doi/10.1515/jbcpp-2022-0123/html?lang=de", "hostname": "degruyter.com", "description": "Idiotype-based therapeutics have failed to deliver their promise, necessitating rethinking of the concept and its potential to develop a viable immunotherapy method. The idiotype based hypothesis is discussed in this paper in order to produce effective anti-idiotype vaccinations. Polyclonal anti-idiotype reagents have been shown to be more successful in animal models, and a better understanding of the immune response in humans supports the idea that polyclonal anti-idiotype vaccines will be more effective than monoclonal-based anti-idiotype vaccines. This innovative approach can be used to produce therapeutic antibodies in a Biotech-standard manner. The idiotype network has been tweaked in the lab to provide protection against a variety of microbiological diseases. Antibodies to image-idiotype antigens, both internal and non-internal, can elicit unique immune responses to antigens. The current outbreak of severe acute respiratory syndrome 2 (SARS-2) has presented a fantastic chance to use idiotype/anti-idiotype antibodies as a protective regimen, which might be used to treat COVID-19 patients. The development of various effective vaccinations has been crucial in the pandemic's management, but their effectiveness has been limited. In certain healthy people, the development of viral variations and vaccinations can be linked to rare off-target or hazardous effects, such as allergic responses, myocarditis and immune-mediated thrombosis and thrombocytopenia. Many of these occurrences are most likely immune-mediated. The current analysis reveals successful idiotype/anti-idiotype antibody uses in a variety of viral illnesses, emphazising their importance in the COVID-19 pandemic.", "sitename": "De Gruyter", "date": "2022-11-01", "cleaned_text": "Abstract Idiotype-based therapeutics have failed to deliver their promise, necessitating rethinking of the concept and its potential to develop a viable immunotherapy method. The idiotype based hypothesis is discussed in this paper in order to produce effective anti-idiotype vaccinations. Polyclonal anti-idiotype reagents have been shown to be more successful in animal models, and a better understanding of the immune response in humans supports the idea that polyclonal anti-idiotype vaccines will be more effective than monoclonal-based anti-idiotype vaccines. This innovative approach can be used to produce therapeutic antibodies in a Biotech-standard manner. The idiotype network has been tweaked in the lab to provide protection against a variety of microbiological diseases. Antibodies to image-idiotype antigens, both internal and non-internal, can elicit unique immune responses to antigens. The current outbreak of severe acute respiratory syndrome 2 (SARS-2) has presented a fantastic chance to use idiotype/anti-idiotype antibodies as a protective regimen, which might be used to treat COVID-19 patients. The development of various effective vaccinations has been crucial in the pandemic's management, but their effectiveness has been limited. In certain healthy people, the development of viral variations and vaccinations can be linked to rare off-target or hazardous effects, such as allergic responses, myocarditis and immune-mediated thrombosis and thrombocytopenia. Many of these occurrences are most likely immune-mediated. The current analysis reveals successful idiotype/anti-idiotype antibody uses in a variety of viral illnesses, emphazising their importance in the COVID-19 pandemic. [anti-idiotype antibody](/search?query=keywordValues%3A%28%22anti-idiotype%20antibody%22%29%20AND%20journalKey%3A%28%22JBCPP%22%29&documentVisibility=all&documentTypeFacet=article); [COVID-19](/search?query=keywordValues%3A%28%22COVID-19%22%29%20AND%20journalKey%3A%28%22JBCPP%22%29&documentVisibility=all&documentTypeFacet=article); [vaccination](/search?query=keywordValues%3A%28%22vaccination%22%29%20AND%20journalKey%3A%28%22JBCPP%22%29&documentVisibility=all&documentTypeFacet=article) - Research funding: None. - Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission. - Competing interests: Yes, all authors state that there is no conflict of interest. - Informed consent: Not required. - Ethical approval: No requirement of ethical approval. References 1. Zumla, A, Chan, JF, Azhar, EI, Hui, DS, Yuen, KY. Coronaviruses\u2014drug discovery and therapeutic options. Nat Rev Drug Discov 2016;15:327-47. [https://doi.org/10.1038/nrd.2015.37](https://doi.org/10.1038/nrd.2015.37). [Suche in Google Scholar](https://scholar.google.com/scholar?q=Zumla%2C%20A%2C%20Chan%2C%20JF%2C%20Azhar%2C%20EI%2C%20Hui%2C%20DS%2C%20Yuen%2C%20KY.%20Coronaviruses%E2%80%94drug%20discovery%20and%20therapeutic%20options.%20Nat%20Rev%20Drug%20Discov%202016%3B15%3A327%E2%80%9347.%20.) [ PubMed ](https://pubmed.ncbi.nlm.nih.gov/26868298/) [ PubMed Central ](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097181/) 2. Lu, R, Zhao, X, Li, J, Niu, P, Yang, B, Wu, H, et al.. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395:565-74. [https://doi.org/10.1016/s0140-6736(20)30251-8](https://doi.org/10.1016/s0140-6736(20)30251-8). [Suche in Google Scholar](https://scholar.google.com/scholar?q=Lu%2C%20R%2C%20Zhao%2C%20X%2C%20Li%2C%20J%2C%20Niu%2C%20P%2C%20Yang%2C%20B%2C%20Wu%2C%20H%2C%20et%20al..%20Genomic%20characterisation%20and%20epidemiology%20of%202019%20novel%20coronavirus%3A%20implications%20for%20virus%20origins%20and%20receptor%20binding.%20Lancet%202020%3B395%3A565%E2%80%9374.%20.) 3. Xu, Z, Shi, L, Wang, Y, Zhang, J, Huang, L, Zhang, C, et al.. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8:420-2. al.. Supramolecular architecture of severe acute respiratory syndrome coronavirus revealed by electron cryomicroscopy. J Virol 2006;80:7918-28. [https://doi.org/10.1128/jvi.00645-06](https://doi.org/10.1128/jvi.00645-06). [Suche Google Central ](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1563832/) 5. Beniac, DR, Andonov, A, Grudeski, E, Booth, PubMed Central ](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097490/) 6. Zhang, H, Penninger, JM, Li, Y, Zhong, N, AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020;46:586-90. [https://doi.org/10.1007/s00134-020-05985-9](https://doi.org/10.1007/s00134-020-05985-9). [Suche in Google Scholar](https://scholar.google.com/scholar?q=Zhang%2C%20H%2C%20Penninger%2C%20JM%2C%20Li%2C%20Y%2C%20Zhong%2C%20N%2C%20Slutsky%2C%20AS.%20Angiotensin-converting%20enzyme%202%20%28ACE2%29%20as%20a%20SARS-CoV-2%20receptor%3A%20molecular%20mechanisms%20and%20potential%20therapeutic%20target.%20Intensive%20Care%20Med%202020%3B46%3A586%E2%80%9390.%20.) [ PubMed ](https://pubmed.ncbi.nlm.nih.gov/32125455/) [ PubMed Central ](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079879/) 7. Hoffmann, M, Kleine-Weber, H, Schroeder, S, Kr\u00fcger, N, Herrler, T, Erichsen, S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181:271-80.e8. [https://doi.org/10.1016/j.cell.2020.02.052](https://doi.org/10.1016/j.cell.2020.02.052). [Suche in Google ](https://pubmed.ncbi.nlm.nih.gov/32142651/) [ Central ](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102627/) 8. Kasuga, Y, Zhu, B, Jang, KJ, Yoo, JS. Innate immune sensing of coronavirus evasion strategies. Exp Mol Med 2021;53:723-36. [https://doi.org/10.1038/s12276-021-00602-1](https://doi.org/10.1038/s12276-021-00602-1). [Suche in Google Central ](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099713/) 9. Varnica, B, Nirupa, G, Allison, PS, Samantha, CW, Christopher, HC, Moulton, VR. Aging, immunity, and COVID-19: how age influences the host immune response to coronavirus infections? Front Physiol 2021;11:1-23. [10.3389/fphys.2020.571416](https://doi.org/10.3389/fphys.2020.571416) [Suche PubMed Central ](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835928/) 10. Iwasaki, A, Pillai, PS. Innate immunity to influenza virus infection. Nat Rev Immunol 2014;14:315-28. [https://doi.org/10.1038/nri3665](https://doi.org/10.1038/nri3665). [Suche in Google Scholar](https://scholar.google.com/scholar?q=Iwasaki%2C%20A%2C%20Pillai%2C%20PS.%20Innate%20immunity%20to%20influenza%20virus%20infection.%20Nat%20Rev%20Immunol%202014%3B14%3A315%E2%80%9328.%20.) [ PubMed ](https://pubmed.ncbi.nlm.nih.gov/24762827/) [ PubMed Central ](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4104278/) 11. Chen, X, Liu, S, Goraya, MU, Maarouf, M, Huang, S, Chen, JL. Host immune response to influenza a virus infection. Front Immunol 2018;9:320. [https://doi.org/10.3389/fimmu.2018.00320](https://doi.org/10.3389/fimmu.2018.00320). [Suche in Google Scholar](https://scholar.google.com/scholar?q=Chen%2C%20X%2C%20Liu%2C%20S%2C%20Goraya%2C%20MU%2C%20Maarouf%2C%20M%2C%20Huang%2C%20S%2C%20Chen%2C%20JL.%20Host%20immune%20response%20to%20influenza%20a%20virus%20infection.%20Front%20Immunol%202018%3B9%3A320.%20.) [ PubMed ](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845129/) 12. Baumgarth, Herman, OC, Jager, GC, Brown, L, Herzenberg, LA, Herzenberg, LA. Innate and acquired humoral immunities to influenza virus are mediated by distinct arms of the immune system. Proc Natl Acad Sci USA 1999;96:2250-5. [https://doi.org/10.1073/pnas.96.5.2250](https://doi.org/10.1073/pnas.96.5.2250). [Suche PubMed ](https://pubmed.ncbi.nlm.nih.gov/10051627/) [ PubMed Central ](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC26769/) 13. Klimpel, GR. Immune defenses, medical microbiology, 4th ed. University of Texas Medical Branch at Galveston; 1996. [Suche in Google Scholar](https://scholar.google.com/scholar?q=Klimpel%2C%20GR.%20Immune%20defenses%2C%20medical%20microbiology%20%2C%204th%20ed.%20University%20of%20Texas%20Medical%20Branch%20at%20Galveston%3B%201996.) 14. Naveed, A, Naz, D, Rahman, SU. Idiotype/anti-idiotype antibodies: as a COVID-19 2021;6:18. [10.1186/s41231-021-00097-y](https://doi.org/10.1186/s41231-021-00097-y) [Suche ](https://pubmed.ncbi.nlm.nih.gov/34458584/) PubMed Central ](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380862/) 15. Bendandi, M. Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma. Rev Anticancer PM, Verroust, LM. an angiotensin II-fab complex at 3 a: hormone recognition by an anti-idiotypic antibody. Science 1992;257:502-7. [https://doi.org/10.1126/science.1636085](https://doi.org/10.1126/science.1636085). [Suche in Google Scholar](https://scholar.google.com/scholar?q=Garcia%2C%20KC%2C%20Ronco%2C%20PM%2C%20Verroust%2C%20PJ%2C%20Br%C3%BCnger%2C%20AT%2C%20Amzel%2C%20LM.%20Three-dimensional%20structure%20of%20an%20angiotensin%20II-fab%20complex%20at%203%20a%3A%20hormone%20recognition%20by%20an%20anti-idiotypic%20antibody.%20Science%201992%3B257%3A502%E2%80%937.%20.) [ PubMed ](https://pubmed.ncbi.nlm.nih.gov/1636085/) MI. Functional validation of ligand [Suche in Google Scholar](https://scholar.google.com/scholar?q=Taub%2C%20R%2C%20Greene%2C%20MI.%20Functional%20validation%20of%20ligand%20mimicry%20by%20anti-receptor%20antibodies%3A%20structural%20and%20therapeutic%20implications.%20Biochemistry%201992%3B31%3A7431%E2%80%935.%20.) [ PubMed ](https://pubmed.ncbi.nlm.nih.gov/1324714/) 18. Wilson, A, George, AJ, King, CA, Stevenson, FK. Idiotypic IgM on a B-cell surface requires processing for recognition by anti-idiotypic T cells. Cell Immunol 1993;147:411-24. [https://doi.org/10.1006/cimm.1993.1080](https://doi.org/10.1006/cimm.1993.1080). [Suche in Google [ PubMed ](https://pubmed.ncbi.nlm.nih.gov/8095858/) 19. Weiss, S, Bogen, B. B-lymphoma cells process and present their endogenous major ](https://pubmed.ncbi.nlm.nih.gov/2492101/) ](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC286448/) 20. ](https://pubmed.ncbi.nlm.nih.gov/49059/) [ PubMed Central ](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC432757/) 21. Reitan, SK, Hannestad, K. The primary IgM antibody repertoire: a source of idiotype immunogens. Yee, HR, Cheng, AYF, Anjum, CE, Kenisi, Y, et al.. Immunomodulatory potential of anti-idiotypic antibodies for the treatment of autoimmune diseases. Future Sci OA 2020;7:FSO648. [https://doi.org/10.2144/fsoa-2020-0142](https://doi.org/10.2144/fsoa-2020-0142). [Suche in Google Scholar](https://scholar.google.com/scholar?q=Pan%2C%20SY%2C%20Chia%2C%20YC%2C%20Yee%2C%20HR%2C%20Cheng%2C%20AYF%2C%20Anjum%2C%20CE%2C%20Kenisi%2C%20Y%2C%20et%20al..%20Immunomodulatory%20potential%20of%20anti-idiotypic%20antibodies%20for%20the%20treatment%20of%20autoimmune%20diseases.%20Future%20Sci%20OA%202020%3B7%3AFSO648.%20.) [ ](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7787174/) 24. Nataraj, Oliverio, MI, Mannon, RB, Mannon, PJ, Audoly, LP, Amuchastegui, CS, et al.. Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J Clin Invest 1999;104:1693-701. [https://doi.org/10.1172/jci7451](https://doi.org/10.1172/jci7451). [Suche in Google Scholar](https://scholar.google.com/scholar?q=Nataraj%2C%20C%2C%20Oliverio%2C%20MI%2C%20Mannon%2C%20RB%2C%20Mannon%2C%20PJ%2C%20Audoly%2C%20LP%2C%20Amuchastegui%2C%20CS%2C%20et%20al..%20Angiotensin%20II%20regulates%20cellular%20immune%20responses%20through%20a%20calcineurin-dependent%20pathway.%20J%20Clin%20Invest%201999%3B104%3A1693%E2%80%93701.%20.) 25. Ruiz-Ortega, Lorenzo, O, Suzuki, Y, Rup\u00e9rez, Sim\u00f5es e Silva, A, Silveira, K, Ferreira, A, Teixeira, M. ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. Br J Pharmacol 2013;169:477-92. [https://doi.org/10.1111/bph.12159](https://doi.org/10.1111/bph.12159). [Suche in Google ](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682698/) 27. Samavati, L, Uhal, BD. ACE2, much more than just a for SARS-COV-2. Front Cell Infect Microbiol 2020;10:317. [https://doi.org/10.3389/fcimb.2020.00317](https://doi.org/10.3389/fcimb.2020.00317). [Suche in Google Scholar](https://scholar.google.com/scholar?q=Samavati%2C%20L%2C%20Uhal%2C%20BD.%20ACE2%2C%20much%20more%20than%20just%20a%20receptor%20for%20SARS-COV-2.%20Front%20Cell%20Infect%20Microbiol%202020%3B10%3A317.%20.) [ PubMed ](https://pubmed.ncbi.nlm.nih.gov/32582574/) [ PubMed Central ](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294848/) 28. Zhao, Y, Kuang, M, Li, J, Zhu, L, Jia, Z, Guo, X, et al.. SARS-CoV-2 spike protein interacts with and [Suche Google ](https://pubmed.ncbi.nlm.nih.gov/33742149/) ](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7975240/) 29. Panariello, F, Cellini, L, Speciani, M, Ronchi, DD, Atti, AR. How does SARS-CoV-2 affect the central nervous system? A working hypothesis. Front Psychiatr 2020;11:582345. [https://doi.org/10.3389/fpsyt.2020.582345](https://doi.org/10.3389/fpsyt.2020.582345). [Suche in Google Scholar](https://scholar.google.com/scholar?q=Panariello%2C%20F%2C%20Cellini%2C%20L%2C%20Speciani%2C%20M%2C%20Ronchi%2C%20DD%2C%20Atti%2C%20AR.%20How%20does%20SARS-CoV-2%20affect%20the%20central%20nervous%20system%3F%20A%20working%20hypothesis.%20Front%20Psychiatr%202020%3B11%3A582345.%20.) [ PubMed ](https://pubmed.ncbi.nlm.nih.gov/33304284/) [ PubMed Central ](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7701095/) 30. Murphy, WJ, Longo, DL. A possible role for anti-idiotype Antibodies in SARS-CoV-2 infection and vaccination. N Engl J Med 2022;386:394-6. [https://doi.org/10.1056/nejmcibr2113694](https://doi.org/10.1056/nejmcibr2113694). in Google Scholar](https://scholar.google.com/scholar?q=Murphy%2C%20WJ%2C%20Longo%2C%20DL.%20A%20possible%20role%20for%20anti-idiotype%20Antibodies%20in%20SARS-CoV-2%20infection%20and%20vaccination.%20N%20Engl%20J%20Med%202022%3B386%3A394%E2%80%936.%20.) 31. Fredriksen, AB, Sandlie, I, Bogen, B. Targeted DNA vaccines for enhanced induction of idiotype-specific B and T cells. Front Oncol 2012;2:154. [https://doi.org/10.3389/fonc.2012.00154](https://doi.org/10.3389/fonc.2012.00154). [Suche in Google Scholar](https://scholar.google.com/scholar?q=Fredriksen%2C%20AB%2C%20Sandlie%2C%20I%2C%20Bogen%2C%20B.%20Targeted%20DNA%20vaccines%20for%20enhanced%20induction%20of%20idiotype-specific%20B%20and%20T%C2%A0cells.%20Front%20Oncol%202012%3B2%3A154.%20.) [ PubMed ](https://pubmed.ncbi.nlm.nih.gov/23115759/) [ PubMed Central ](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483591/) 32. Li, B, Peng, J, Niu, Z, Yin, X, Liu, F. Preparation of anti-idiotypic antibody against avian influenza virus subtype H9. Cell Mol 2005;2:155-7. Intravenous immunoglobulin therapy: how does IgG Rev Immunol 2013;13:176-89. [https://doi.org/10.1038/nri3401](https://doi.org/10.1038/nri3401). [Suche in Google Scholar](https://scholar.google.com/scholar?q=Schwab%2C%20I%2C%20Nimmerjahn%2C%20F.%20Intravenous%20immunoglobulin%20therapy%3A%20how%20does%20IgG%20modulate%20the%20immune%20system.%20Nat%20Rev%20Immunol%202013%3B13%3A176%E2%80%9389.%20.) [ AA, Habiballah, SB, Platt, CD, Geha, RS, Chou, JS, McDonald, DR. Immunoglobulins in the treatment of COVID-19 infection: proceed with caution. Clin Immunol 2020;216:108459. [https://doi.org/10.1016/j.clim.2020.108459](https://doi.org/10.1016/j.clim.2020.108459). [Suche PubMed Central ](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211658/) 35. Merimsky, O, Fishman, P, Shoenfeld, Y. Cancer therapy with anti-idiotypic antibodies. In: Shoenfeld, RC, Markella, Z, Aikaterini, H. Natural autoantibodies in health and disease, reference module in biomedical sciences. Athens, Greece: Elsevier; 2022. [Suche in Google Scholar](https://scholar.google.com/scholar?q=Peggy%2C%20L%2C%20Markella%2C%20Z%2C%20Aikaterini%2C%20H.%20Natural%20autoantibodies%20in%20health%20and%20disease%2C%20reference%20module%20in%20biomedical%20sciences%20.%20Athens%2C%20Greece%3A%20Elsevier%3B%202022.) 39. Kohen, G, Boever, JD. Chapter 19 - noncompetitive immunoassay for small World Organization. WHO Coronavirus (COVID-19) dashboard [Home page in Internet]. Available "}